CN116490165A - 阿比特龙前药 - Google Patents

阿比特龙前药 Download PDF

Info

Publication number
CN116490165A
CN116490165A CN202180070124.5A CN202180070124A CN116490165A CN 116490165 A CN116490165 A CN 116490165A CN 202180070124 A CN202180070124 A CN 202180070124A CN 116490165 A CN116490165 A CN 116490165A
Authority
CN
China
Prior art keywords
abiraterone
subject
oil
decanoate
prostate cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180070124.5A
Other languages
English (en)
Chinese (zh)
Inventor
马修·J·夏普
威廉·R·小莫尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lopera Treatment Co
Original Assignee
Lopera Treatment Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lopera Treatment Co filed Critical Lopera Treatment Co
Publication of CN116490165A publication Critical patent/CN116490165A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN202180070124.5A 2020-09-02 2021-09-01 阿比特龙前药 Pending CN116490165A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063073502P 2020-09-02 2020-09-02
US63/073,502 2020-09-02
PCT/US2021/048607 WO2022051330A1 (en) 2020-09-02 2021-09-01 Abiraterone prodrugs

Publications (1)

Publication Number Publication Date
CN116490165A true CN116490165A (zh) 2023-07-25

Family

ID=77951832

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180070124.5A Pending CN116490165A (zh) 2020-09-02 2021-09-01 阿比特龙前药

Country Status (9)

Country Link
US (1) US20240050447A1 (https=)
EP (1) EP4208171A1 (https=)
JP (1) JP7850366B2 (https=)
CN (1) CN116490165A (https=)
AU (1) AU2021338271A1 (https=)
CA (1) CA3189989A1 (https=)
IL (1) IL300837A (https=)
MX (1) MX2023002478A (https=)
WO (1) WO2022051330A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10792292B2 (en) 2019-03-06 2020-10-06 Propella Therapeutics, Inc. Abiraterone prodrugs
US11957696B2 (en) 2021-02-15 2024-04-16 Propella Therapeutics, Inc. Abiraterone prodrugs
WO2024107928A1 (en) 2022-11-16 2024-05-23 Propella Therapeutics, Inc. Abiraterone decanoate composition and use in therapy
CN116287275B (zh) * 2023-04-10 2024-04-05 广州市第一人民医院（广州消化疾病中心、广州医科大学附属市一人民医院、华南理工大学附属第二医院） Ptgr1作为cdk4/6抑制剂与二甲双胍联合用药指导标志物的应用
WO2025240673A1 (en) * 2024-05-15 2025-11-20 Cardiff Oncology, Inc. Cancer treatment using akt inhibitors and plk1 inhibitors

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104017045A (zh) * 2014-06-23 2014-09-03 广州艾格生物科技有限公司 甾体cyp17抑制剂的新型药物前体及其应用、制备方法
US20150337003A1 (en) * 2013-01-18 2015-11-26 Cortendo Ab (Publ) Abiraterone and analogs thereof for the treatment of diseases associated with cortisol overproduction
CN114026106A (zh) * 2019-03-06 2022-02-08 普洛拉治疗公司 阿比特龙前药

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20121788A1 (it) * 2012-10-22 2014-04-23 Olon Spa Procedimento per la purificazione di abiraterone acetato
US10722527B2 (en) * 2015-04-10 2020-07-28 Capsugel Belgium Nv Abiraterone acetate lipid formulations
EP3394080B1 (en) * 2015-12-23 2023-06-07 The University Of British Columbia Lipid-linked prodrugs
CN106977577A (zh) * 2017-04-21 2017-07-25 湖南师范大学 两类阿比特龙衍生物的合成
WO2020081999A1 (en) 2018-10-18 2020-04-23 Essa Pharma, Inc. Androgen receptor modulators and methods for their use
US11957696B2 (en) * 2021-02-15 2024-04-16 Propella Therapeutics, Inc. Abiraterone prodrugs
JP2024533332A (ja) * 2021-09-08 2024-09-12 プロペラ セラピューティクス インコーポレイテッド 経口アビラテロン製剤
CA3243913A1 (en) * 2022-03-01 2023-09-07 Astellas Us Llc Abiraterone prodrugs

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150337003A1 (en) * 2013-01-18 2015-11-26 Cortendo Ab (Publ) Abiraterone and analogs thereof for the treatment of diseases associated with cortisol overproduction
CN104017045A (zh) * 2014-06-23 2014-09-03 广州艾格生物科技有限公司 甾体cyp17抑制剂的新型药物前体及其应用、制备方法
CN114026106A (zh) * 2019-03-06 2022-02-08 普洛拉治疗公司 阿比特龙前药

Also Published As

Publication number Publication date
EP4208171A1 (en) 2023-07-12
US20240050447A1 (en) 2024-02-15
MX2023002478A (es) 2023-03-27
JP2023539371A (ja) 2023-09-13
WO2022051330A1 (en) 2022-03-10
IL300837A (en) 2023-04-01
CA3189989A1 (en) 2022-03-10
AU2021338271A1 (en) 2023-03-30
JP7850366B2 (ja) 2026-04-23

Similar Documents

Publication Publication Date Title
US11957696B2 (en) Abiraterone prodrugs
CN114026106B (zh) 阿比特龙前药
CN116490165A (zh) 阿比特龙前药
US20250025417A1 (en) Oral abiraterone formulations
JP2025508944A (ja) アビラテロンプロドラッグ
HK40096900A (zh) 阿比特龙前药
HK40120426A (zh) 阿比特龙前药
RU2822219C2 (ru) Пролекарства абиратерона
HK40096901A (zh) 阿比特龙前药
WO2024107928A1 (en) Abiraterone decanoate composition and use in therapy
HK40065545A (en) Abiraterone prodrugs
HK40103488A (en) Abiraterone prodrugs
HK40130201A (zh) 阿比特龙前药
HK40065545B (zh) 阿比特龙前药

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40096900

Country of ref document: HK